Abevmy 25 mg/mL concentrate for solution for infusion.

DRUG4 trials

Sponsors

Centre Hospitalier Universitaire De Grenoble, Exscientia AI Limited, Hopital Fondation Adolphe De Rothschild, Institut De Cancerologie De L Ouest

Conditions

Advanced solid tumorsPatients with newly diagnosed advanced peritoneal metastasis from colorectal cancercerebral arteriovenous malformationsunresectable hepatocellular carcinoma

Phase 1

A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors

RecruitingCTIS2023-508227-13-00

Exscientia AI LimitedAdvanced solid tumors

Start: 2023-06-19Target: 112Updated: 2026-01-14

Phase 2

Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER

CompletedCTIS2022-502078-17-00

Centre Hospitalier Universitaire De Grenobleunresectable hepatocellular carcinoma

Start: 2022-12-15End: 2024-03-08Target: 196Updated: 2023-08-22

BevacizuMAV : Evaluation of the efficacy and safety of anti-angiogenic treatment with intravenous bevacizumab in patients with symptomatic cerebral arteriovenous malformations

RecruitingCTIS2023-508464-30-00

Hopital Fondation Adolphe De Rothschildcerebral arteriovenous malformations

Start: 2024-10-24Target: 54Updated: 2025-06-27

Systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy (PIPAC) for colon peritoneal metastases – a multicentre phase II randomized trial (PIPOX02)

RecruitingCTIS2024-514560-10-00

Institut De Cancerologie De L OuestPatients with newly diagnosed advanced peritoneal metastasis from colorectal cancer

Start: 2025-06-12Target: 114Updated: 2024-10-11